VisEn Medical Inc. has entered into a joint research program to expand the capabilities and accelerate the adoption of in vivo fluorescence technologies in Eli Lilly and Co.'s research and development programs. Lilly has been working with VisEn’s portfolio of in vivo fluorescence probes and Fluorescence Molecular Tomography imaging systems as part of its new molecular imaging center and preclinical development programs.
This research program is intended to further the development and expand the application of VisEn's fluorescence in vivo imaging technologies in pharmaceutical drug development. VisEn's fluorescence imaging technologies and products help in identifying, characterizing and quantifying a range of biological processes in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research and more efficient drug development. VisEn's technologies are designed for biocompatibility and translation from preclinical imaging to clinical imaging.